Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
Author(s): Giulia Magnani , Marco Valgimigli Added: 3 years ago
Dual antiplatelet therapy (DAPT), defined as the use of a P2Y12 receptor inhibitor (clopidogrel, ticagrelor or prasugrel) and aspirin, is required after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).1 Although the use of DES has been shown to reduce the rate of restenosis as compared with bare-metal stents (BMS), there is concern that DES may be associated with a higher… View more

Anticoagulation

Prevention & Chronic Conditions
Author(s): Gaku Nakazawa , Masataka Nakano , Marc Vorpahl , et al Added: 3 years ago
The limited information regarding the long-term safety of drug-eluting stents (DES) for the treatment of ST-segment-elevation myocardial infarction (STEMI) has raised concern regarding its clinical safety, in particular with respect to the associated morbidity and mortality attributed to late stent thrombosis (LST). Observational studies in daily practice have shown that the risk of LST continues… View more

MI/ACS

Intervention
Author(s): Robert A Byrne , Eric Eeckhout , Gennaro Sardella , et al Added: 3 years ago
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are established strategies for revascularisation in patients with coronary artery disease. While CABG was the standard of care for patients with multivessel disease, the introduction of baremetal stents (BMSs) and, later, drug-eluting stents (DESs) has led to an increased use of PCI in these more challenging cases… View more

Prevention & Chronic Conditions

Intervention
Author(s): Robert Gil , Dobrin Vassilev , Jacek Bil Added: 3 years ago
The treatment of coronary bifurcation lesions (BL) is still challenging for interventional cardiologists, due to the relatively high-risk of the side branch (SB) closure and the increased long-term restenosis.1 The idea of a dedicated bifurcation stent (DBS) was proposed as a solution for problems associated with the BL treatment by means of a classical stent.1 Three groups of stents are… View more

Intervention
Author(s): Katrina Mountfort Added: 3 years ago
Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris The use of second-generation polymeric metallic drug-eluting stents (DES) in percutaneous coronary intervention (PCI) is now routine practice and has demonstrated excellent safety and efficacy compared with first-generation DES. These stents have enhanced PCI procedures, enabling the treatment of more complex lesions and… View more

Prevention & Chronic Conditions

Intervention
Author(s): Walter Desmet Added: 3 years ago
Since its introduction in 1977, the long-term benefits of percutaneous coronary intervention have been limited by the phenomenon of restenosis, i.e. the recurrence of significant stenosis at the site of intervention. While in restenosis after plain balloon angioplasty roughly two-thirds of the late lumen loss is due to negative vessel wall remodelling, the late lumen loss after stent implantation… View more

Intervention
Author(s): Rhidian J Shelton , Daniel J Blackman Added: 3 years ago
The introduction of coronary stents in the late 1980s improved outcome over balloon angioplasty via a reduction in acute vessel closure, prevention of vessel recoil, increase in acute gain and a lower rate of clinical restenosis.1,2 However, in-stent restenosis (ISR), caused by smooth-muscle cell proliferation and migration, leading to neointimal hyperplasia, remains the Achilles’ heel of bare… View more

Imaging & Diagnostics

MI/ACS
Author(s): Pantelis Diamantouros , David Kandzari Added: 3 years ago
In both randomised trials, compared with bare metal coronary stents, and in observational registries, treatment with drug-eluting stents (DES) has been associated with considerable reductions in angiographic restenosis and the need for repeat coronary revascularisation procedures. Despite these established benefits in selected patient populations, relatively little is known regarding the safety… View more

MI/ACS

Intervention
Author(s): Adnan Kastrati Added: 3 years ago
Compared with conventional bare-metal stents (BMS), the introduction of drug-eluting stents (DES) has resulted in a substantial reduction in the incidence of in-stent restenosis.1 DES systems eluting either sirolimus2 or paclitaxel3 from a polymer stent coating have been shown in randomised trials to effectively inhibit the process of neointimal proliferation, resulting in restenosis reduction. … View more

Intervention
Author(s): Corrado Tamburino , Davide Capodanno Added: 3 years ago
Recently, many eminent scientific journals have published long-term follow-up data from both randomised clinical trials (RCTs) and registries of patients treated with percutaneous coronary intervention (PCI) undergoing drug-eluting stent (DES) implantation. In fact, this is the only course of action to address the concerns regarding DES safety that were first raised almost two years ago.1… View more

Intervention